MYC and diffuse large B-cell lymphoma: To date, a single large retrospective registry-based analysis utilizing targeted sequencing, without copy number alterations (CNAs) data, has produced consistent results with the National Cancer Institute (NCI) classifier [4] and has validated the prognostic impact of specific genetic subtypes (i.e., N1, EZB-MYC) in R-CHOP-treated DLBCL patients.